Articles On PainChek (ASX:PCK)

Painchek is awaiting US approval for its digital pain-assessment tool The US aged-care market is ten times bigger than Australia’s The company is also eyeing the much bigger infant market   PainChek (ASX:PCK) CEO Philip Daffas has a simpl...

PainChek Ltd (ASX:PCK) has raised $5.1 million through a capital raising initiative aiming to boost the market footprint of its adult pain assessment and monitoring application, in addition to ensuring completion of activities to enable the...

The ASX200 has been down 0.34% at 8,345 points, as the bourse pulls back from yesterday’s record highs. Gold continues to jump, with rising demand for haven assets following an escalation of tensions in Russia’s invasion of Ukraine. Bull...

Painchek is eyeing a market of 1.7 million US aged-care beds for its pain-detection device Genetic Signatures sizes up a $400 million US market The latest thrills and spills at life sciences AGMs   PainChek (ASX:PCK) lodged a US Food &amp...

PainChek (ASX:PCK) has applied for Food and Drug Administration (FDA) De Novo approval for its new PainChek Adult App. The application comes hot on the heels of completion of a US-based validation study. A green light from the FDA wou...

  Philip Daffas – CEO & Managing Director – PainChek Limited (ASX:PCK) is a digital health company that offers a mobile app for pain assessment, using AI to analyse facial expressions and other indicators in patients unable to communica...

ASX rises  following Wall Street’s lead Cettire drops 12pc after disappointing earnings update Retail house Premier Investments surge after potential Myer deal   The ASX rose by 0.34% on Tuesday following Wall Street’s lead. Consumer dis...

PainChek (ASX: PCK) has announced positive outcomes from a US clinical validation study that will allow the company to progress with a Food and Drug Administration (FDA) De Novo submission for its Adult smartphone app. The study recruited 1...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...

Argent Biopharma packs its bags for London on a one-way ticket Patrys shares slump 50% on cancellation of key drug program Painchek targets US market for its pain detection app   Health Check is renowned biotech journo Tim Boreham’s daily...

PainChek (ASX:PCK) has updated the market on the progress of its De Novo submission to the US FDA for its flagship app in aged care settings. The company reported on Wednesday the FDA’s overall Clinical Evaluation Report (CER) drawing fr...

PainChek granted patent in Europe PainChek (ASX:PCK) has been granted a patent in 20 European nations by the European Patent Office (EPO). The patent was given for the PainChek app, an AI platform designed to analyse facial expressions, voc...

  Peter Milios: I'm Peter Milios from the Finance Use Network, and today I'm talking with PainChek. PainChek, trading under the ASX Code PCK with a market capitalization of 45 million, is the developer of the world's first smart-based pain...

  To register for Friday's webinar click here. PainChek (ASX:PCK), developer of the world’s first smart based pain assessment and monitoring application, has announced it has established a reseller agreement with Nourish Care, a leading UK...

14 Mar 2024 - A snapshot of the stocks on the move, featuring PainChek (ASX:PCK), Chimeric Therapeutics (ASX:CHM) and Torque Metals (ASX:TOR).

After a day of profit taking yesterday, the ASX200 is set to stablilise, with futures tipping a 0.2 per cent rise. US markets traded mostly flat, although the Nasdaq shed 0.4 per cent ahead of US inflation data due to land late tonight o...

  Philip Daffas, CEO & Managing Director, PainChek (ASX:PCK) develops mobile medical applications intended to provide pain assessment for people who cannot communicate with their carers.

  ASX200 dragged down by bad drugs The IT Sector is up 1.1pc, Healthcare is down about 3.2pc Small cap winners led by American Rare Earths and Appen   The benchmark was shot through the heart by CSL this morning leaving everything else in...

ASX medical devices to make inroads with FDA after a good year for drug developers FDA is reviewing Allegra’s Spinal Cage Device made from 3D-printed Sr-HT-Gahnite Stockhead reached out to Allegra’s board member, Dr Nick Hartnell   It’s b...

PainChek’s European patent HeraMed signs deal with Telstra AdAlta announced interim Phase 1 results Avita lowers 2023 guidance PainChek’s European patent application accepted PainChek (ASX: PCK) announced that the European Patent Office...

  Philip Daffas – CEO & Managing Director – PainChek (ASX:PCK) develops mobile medical applications intended to provide pain assessment for people who cannot communicate with their carers.

Stockhead’s Top 10 at shortly-before-11-ish, fuelled by caffeine and rage, because it’s Friday and those are the only two things I have in sufficient quantity to produce any kind of energy today. Top 10 highlights the best (and sometimes wo...

Benchmark index finishes higher on strong oil prices ASX Sectors led by oil-driven gains for Energy Fin Resources banks a banger to be Monday’s small cap legend   The ASX200 found some enthusiasm for living on Monday arvo, supported abl...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

What stocks trading at 52-week highs are telling us How do we know if they are overbought or oversold? We take a look at one investing strategy called the 52-Week High Rotation Strategy   One indicator used by chartists to determine an en...

Welcome to Market Close From The Floor at the Critical Minerals and Energy Investment Conference in Perth. It’s the final day of a busy week of commodity events here, where investors have had the opportunity to meet with the leaders of c...

Benchmark slides throughout the day after a shocker on Wall Street last night. Utilities did best but still ended up losing, down 0.3% for the day. Paincheck a ray of sunshine this afternoon, up 33% today despite an early speeding ticket....

ASX biotech stock PainChek Ltd (ASX: PCK) rocketed 36% higher this afternoon, prompting the ASX to issue a price query. The Painchek share price hit a new 52-week high of 4.6 cents today. It has since slipped back to 4.3 cents at the clos...

PainChek (PCK) secures firm commitments to raise $3.55 million through a share placement The company will issue 131.5 million fully paid ordinary shares at 27 cents each, a 3.6 per cent discount to the company’s last traded price on Mond...

The $36 million ASX-listed company had Canaccord Genuity rounding up investors at 2.7¢ a pop.

ASX200 ends choppy day 0.2% higher Miners and med stocks offset banks and Energy  Small caps led by NickelSearch, Odin   All shook up, but home alive – Aussie shares somehow brought home the bacon on Tuesday, with both the All Ords and...

The Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health and Telehealth also received significant funding allocations Here are the ASX stocks that could benefit   Medicare, telehealth and mental...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

PainChek (PCK) is expanding into Japan after being accepted into the JETRO Business Connect program for 2022JETRO is Japan’s main governmental organisation for promoting foreign business and allows companies who are wanting invest in Japan...

Botanix submits NDA to the US FDA Pharmaxis reports on latest clinical trials PainChek to expand to Japan Clinical dermatology company Botanix Pharma (ASX:BOT) has submitted a New Drug Application (NDA) to the US FDA for Sofpironium Bromi...

PainChek (PCK) receives funding for a 12-month pilot program in care environments across Wales The developer of a smart phone-based pain assessment and monitoring app received the funding from the Gwent Regional Partnership board in Wales...

ShareCafeWebinar Recap – PCK, OCC, LCL & ICE Catch up on the full webinar presentations from PainChek (ASX: PCK), Orthocell (ASX: OCC), Los Cerros (ASX: LCL) & icetana (ASX: ICE) Webinar Recap – PCK, OCC, LCL & ICEStaff Writers

ShareCafePainCheck (ASX: PCK) – Webinar presentation Philip Daffas – CEO & MD – PainChek is transforming pain management by using facial recognition and artificial intelligence to detect pain. More PainChek content PainCheck (ASX: PCK)...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

PainChek (PCK) receives a $392,820 grant from the Western Australia State Government’s Future Health Research and Innovation Fund The grant is for the company’s project to develop a specific version of PainChek for non-verbal children livi...

PainChek (PCK) hopes to raise $4.59 million through an entitlement offer and share placement to accelerate its commercial rollout Under the entitlement offer, eligible shareholders can subscribe for one new share for every 20 shares held a...

Avita Medical makes spray on skin for burns and soft tissue injuries HITIQ’s concussion tech is popular for athletes and sports teams PainChek’s smartphone app can tell if babies or older Aussies are in pain There’s a plethora of biotech...

Tech leads losses on local markets ASX 200 gives away early gains, XEC dives more than 1% again BNPL names big and small get smaller   Small Caps are sharply lower and the ASX 200 is wandering aimlessly on Wednesday as tech names tumble...

PainChek (PCK) enters a mid-week trading halt regarding the release of a placement and non-renounceable entitlement offer announcement The company will remain in the halt until June 24 or when the announcement is released, whichever occurs...

It’s still dead quiet in equity capital markets, but two microcaps were out testing the waters after the ASX200 closed in green on Tuesday. 

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

The healthcare sector is Australia’s biggest employer, employing 1 in 7 Aussies or roughly two million people. Treasurer Josh Frydenberg announced last night that Australia’s health budget will top $132bn in 2022-23, up from $62bn a decade...

PainChek (PCK) is rolling out its pain assessment solution through retirement village and aged care service provider Summerset, following a successful six-month trial This 12 month contract is the first rollout of PainChek in New Zealand U...

Oncosil’s medical device will be used in a German government funded clinical trial PainChek to expand its technology in New Zealand Oncosil gets green light in Germany Medical device company OncoSil (ASX:OSL) announced that Germany has ap...

ASX to rise to start Budget week The Treasury will deliver its 2022/23 Federal Budget at 7pm on Tuesday (tomorrow), earlier than normal due to the May election.  JP Morgan expects the forecast Budget deficit to come in at $80 billion. Local...